Breast Cancer Screening: Mammograms, Guidelines, and What to Know
Written by North Editorial Staff | Clinically reviewed by Laura Morrissey, RN, BSN | Last reviewed: March 2026
Key Takeaways
Mammography is the standard breast cancer screening tool for average-risk women and is the only imaging modality consistently shown to reduce breast cancer mortality in large randomized trials.
The American Cancer Society recommends that average-risk women begin annual mammograms at age 40. Other organizations recommend starting at 45 or 50 — understanding the guideline differences helps you make an informed decision with your doctor.
Women at elevated risk — due to a BRCA mutation, strong family history, or prior chest radiation — should begin screening earlier and may benefit from annual breast MRI in addition to mammography.
Dense breast tissue reduces mammogram sensitivity. If you have dense breasts, ask your doctor whether supplemental ultrasound or MRI screening is appropriate.
Screening mammograms reduce breast cancer mortality by detecting cancer at earlier, more treatable stages — the evidence base is strong, particularly for women in their 40s and 50s.
Feeling anxious about screening is normal. A call-back after a mammogram is common (about 10% of women) and most call-backs turn out to be benign.
Why Breast Cancer Screening Matters
Breast cancer screening exists for one purpose: to find cancer before it causes symptoms, when it is most treatable. When breast cancer is detected at Stage I or earlier, the 5-year relative survival rate is approximately 99%. When detected at Stage IV, that rate drops to approximately 29%.
Regular screening mammography has been shown in multiple large randomized controlled trials to reduce breast cancer mortality — the evidence is particularly strong for women in their 40s and 50s, though the benefit extends across age groups. According to a 2015 analysis published in JAMA Internal Medicine, mammography screening has contributed meaningfully to the decline in breast cancer mortality seen over the past three decades.
The key questions for most women are: when should I start, how often should I go, and does my personal risk level require anything beyond a standard mammogram?
Mammography: What It Is and How It Works
A mammogram is a low-dose X-ray of the breast tissue. During the procedure, each breast is compressed between two plates. Compression spreads the tissue apart, reduces the radiation dose needed, and produces clearer images. The compression is brief (a few seconds) and may be uncomfortable, but it is not harmful.
Modern mammography has evolved significantly:
2D mammography (film or digital): The traditional approach, still widely used and effective.
3D mammography (tomosynthesis): Creates a series of thin image slices through the breast rather than a single flat image. Multiple studies have shown that 3D mammography detects more cancers and reduces false-positive call-back rates compared with standard 2D mammography. It has become increasingly standard at most screening facilities.
Both 2D and 3D mammography are covered by insurance for screening purposes under the Affordable Care Act.
Breast Cancer Screening Guidelines
Multiple major medical organizations have published mammography screening guidelines. They differ primarily in the recommended starting age and screening interval. These differences reflect varying interpretations of the balance between the benefit of early detection and the potential harm of false-positive results (which cause anxiety and lead to additional testing, and occasionally unnecessary biopsy).
American Cancer Society (ACS) — 2015 Guidelines
Age 40–44: Women should have the opportunity to begin annual screening mammography if they choose.
Age 45–54: Annual mammograms are recommended.
Age 55 and older: Women may transition to mammograms every 2 years, or continue annually. Annual mammography remains an option for any woman who prefers it.
Women should continue screening as long as they are in good health and expected to live at least 10 more years.
U.S. Preventive Services Task Force (USPSTF) — 2024 Updated Recommendations
Age 40–74: Biennial (every 2 years) screening mammography is recommended for all women.
The 2024 update lowered the starting age from 50 to 40, primarily in response to evidence of benefit and rising breast cancer incidence in younger women.
American College of Radiology (ACR) and Society of Breast Imaging (SBI)
Annual mammograms beginning at age 40 for average-risk women.
Risk assessment at age 25 to identify women who need earlier or more intensive screening.
What This Means for You
The variation in guidelines can be confusing. A practical takeaway: annual mammograms beginning at age 40 are supported by substantial evidence, endorsed by the American Cancer Society and ACR, and now consistent with the USPSTF update. The most important step is to start screening — the specific interval can be discussed with your doctor based on your personal risk profile and preferences.
High-Risk Screening: When Mammography Alone Is Not Enough
For women at elevated breast cancer risk, mammography alone may not be sufficient. The American Cancer Society recommends annual breast MRI in addition to mammography for women who meet certain high-risk criteria:
Known BRCA1 or BRCA2 mutation (or an untested first-degree relative of a BRCA carrier)
Estimated lifetime risk ≥20% based on validated risk models (such as Tyrer-Cuzick or BOADICEA)
Radiation therapy to the chest between ages 10 and 30 (e.g., for Hodgkin lymphoma)
Certain hereditary syndromes: Li-Fraumeni syndrome (TP53 mutation), Cowden syndrome (PTEN mutation), Bannayan-Riley-Ruvalcaba syndrome
For these women, MRI is recommended in addition to mammography — not instead of it. Mammography and MRI detect different things and are complementary. The combination catches more cancers than either test alone.
When to begin high-risk screening: Typically, women with BRCA mutations or equivalent risk begin annual MRI and mammography at age 25–30, unless an earlier start is indicated by family history. A high-risk program at a comprehensive cancer center can help determine the right timing and protocol for your specific situation.
Women at intermediate risk (lifetime risk 15–20%) may benefit from supplemental MRI screening on an individual basis — the decision should be made in consultation with a physician.
Dense Breast Tissue and Screening
Dense breast tissue is one of the most important factors affecting mammogram performance. Breasts are described as dense when they contain more glandular and fibrous tissue relative to fatty tissue. About 40–50% of women have dense or extremely dense breasts, according to published data from the ACR.
Dense tissue affects screening in two ways:
Reduced sensitivity: Dense tissue and tumors both appear white on a mammogram. Tumors can be harder — or impossible — to see against a dense background. A mammogram’s sensitivity drops from approximately 85–90% in fatty breasts to 50–60% in extremely dense breasts.
Independently elevated risk: Women with very dense breasts have a modestly higher risk of developing breast cancer — approximately 1.5–2 times the average risk — independent of other factors.
As of 2023, federal law (the Mammography Quality Standards Act update) requires that all mammography providers notify patients of their breast density in their results letter and recommend they discuss supplemental screening with their physician.
Supplemental Screening Options for Dense Breasts
Whole-breast ultrasound: Can detect cancers not visible on mammogram in dense tissue. It does generate more false positives (findings requiring follow-up that turn out to be benign) than mammography. Cost and insurance coverage vary by state and insurer.
Breast MRI: The most sensitive supplemental option, but also the most expensive and most likely to produce false positives. Generally recommended for high-risk women; evidence is growing for intermediate-risk women with dense tissue.
Contrast-enhanced mammography (CEM): Uses contrast dye with mammography to highlight areas with increased blood flow. Emerging data suggest it approaches MRI sensitivity with better specificity.
Talk with your doctor about which supplemental screening option, if any, is right for your specific combination of breast density and personal risk.
What Happens During and After a Mammogram
Preparation: Avoid scheduling a mammogram in the week before your period, when breasts are often more tender. On the day of the exam, do not apply deodorant, antiperspirant, lotion, or powder to the breasts or underarms as these residues can appear on the image. Wear a two-piece outfit for easy undressing.
The exam: Each breast is positioned and compressed between the imaging plates. Standard mammography takes 2–4 images per breast. Including setup, most mammograms take 15–30 minutes. Compression is brief (several seconds) and may cause discomfort or pressure, but should not cause lasting pain.
Getting results: Most mammogram results are available within a few days. Results are sent to you and your ordering physician. Under the Mammography Quality Standards Act, you must receive written results.
If you’re called back: A call-back for additional imaging does not mean cancer has been found. About 10% of women who have screening mammograms are asked to return for more views or ultrasound. The vast majority of call-backs lead to a benign finding or short-interval follow-up recommendation, not biopsy or cancer diagnosis.
BI-RADS scoring: Your report will include a BI-RADS score (0–6). Scores 1 and 2 are normal or benign. Score 3 typically means short-interval follow-up in 6 months. Scores 4 and 5 indicate biopsy is recommended. Score 6 means cancer has already been confirmed.
Self-Exams and Clinical Breast Exams
Breast self-examination (BSE) — systematic self-examination of the breasts — was once widely recommended but is no longer endorsed as a formal screening tool by most major guidelines, as research has not shown it reduces breast cancer mortality and it is associated with more benign biopsies. However, breast self-awareness — being familiar with how your breasts look and feel, and reporting any new changes to your doctor promptly — is encouraged.
Clinical breast exam (CBE) — physical examination by a clinician — is no longer universally recommended as a screening tool for average-risk women by the ACS (evidence of benefit is limited when mammography is also being performed). However, CBEs are still performed in many clinical settings, particularly as part of gynecologic care, and are appropriate for women who have not undergone mammography.
Screening and Clinical Trials
Breast cancer screening guidelines continue to evolve as new evidence emerges. Current trials are investigating the value of AI-assisted mammogram reading, risk-stratified screening intervals (tailoring frequency to individual risk rather than applying a uniform recommendation), and novel screening technologies. The answers these trials generate will shape recommendations for the next generation.
If you are at high risk or navigating a complex screening situation, a comprehensive breast cancer program can help develop a personalized screening plan. You can also explore breast cancer clinical trials to see whether any screening or prevention trials are relevant for you.
Frequently Asked Questions
At what age should I start getting mammograms?
For average-risk women, the American Cancer Society recommends annual mammograms starting at age 40, with the option to start at 40–44 and transition to annual starting at 45. The USPSTF (updated 2024) recommends biennial mammograms starting at 40. Most breast cancer specialists and radiologists recommend annual mammograms starting at 40, as annual screening detects more cancers and at earlier stages than biennial screening. Women at elevated risk should begin earlier — typically 25–30, depending on their specific risk.
What is a 3D mammogram and is it better than a regular mammogram?
A 3D mammogram (tomosynthesis) takes multiple X-ray images from different angles to create a layered, three-dimensional picture of the breast, rather than a single flat image. Multiple studies have shown 3D mammography detects more cancers, especially in women with dense breasts, and reduces the rate of call-backs for additional imaging compared with standard 2D mammography. It has become increasingly standard at most facilities.
What does it mean to have dense breasts?
Dense breasts contain more glandular and fibrous tissue relative to fatty tissue — about 40–50% of women have dense or extremely dense breasts. Dense tissue appears white on a mammogram, as do tumors, which makes cancers harder to see. Dense breasts are also independently associated with a modestly higher risk of breast cancer. If your mammogram report says you have dense breasts, discuss supplemental screening options with your doctor.
Is mammography safe? Does radiation from mammograms cause cancer?
Mammography uses a small amount of radiation, but the dose is very low — a screening mammogram delivers approximately the same radiation as 7 weeks of natural background radiation. Large-scale studies have not demonstrated that mammography causes meaningful increases in cancer risk, and the benefit of early detection in reducing breast cancer mortality substantially outweighs this theoretical risk.
I was called back after my mammogram. Does that mean I have cancer?
A call-back is common — approximately 10% of women who have screening mammograms are asked to return for additional imaging. This most often means the radiologist wants a different view or wants to use ultrasound to better evaluate a specific area. The majority of call-backs do not result in a cancer diagnosis. It is understandably anxiety-provoking, but a call-back is a routine part of the screening process, not a diagnosis.
References
American Cancer Society. (2015). Breast Cancer Early Detection: ACS Guidelines for Breast Cancer Screening. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
U.S. Preventive Services Task Force. (2024). Breast Cancer Screening: Recommendation Statement. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
American College of Radiology. (2023). ACR Breast Cancer Screening Guidelines. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Bi-Rads
Brawley, O., et al. (2015). Special Report: New Mammography Screening Guidelines from the American Cancer Society. CA: A Cancer Journal for Clinicians. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21312
Rafferty, E. A., et al. (2013). Assessing Radiologist Performance Using Combined Digital Mammography and Breast Tomosynthesis Compared with Digital Mammography Alone. Radiology. https://doi.org/10.1148/radiol.12120169
Gradishar, W. J., et al. (2024). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419